title: Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.
abstract: The introduction of plerixafor has enabled successful collection of stem cells in the majority of patients with lymphoma or myeloma in whom previous attempts at mobilization have failed. However, a proportion of patients have been shown to be resistant to this mobilization regimen. To identify the factors that impair stem cell mobilization and collection with plerixafor, we reviewed the data for 197 patients who had undergone mobilization with plerixafor and granulocyte-colony stimulating factor in Central Europe. Predictors of mobilization failure were evaluated using logistic regression analysis. Among the 197 patients mobilized, the target of ≥2.0 × 10(6) CD34+ cells/kg was collected from 133 (67.5%). Our analysis revealed that previous treatment with lenalidomide, bortezomib, melphalan, radiotherapy, or autologous stem cell transplantation and regimen of plerixafor use in combination with chemotherapy had no significant effect on the efficiency of collection. In contrast, an age ≥65 years (odds ratio 0.331, 95% CI: 0.112-0.977, P < 0.05), a diagnosis of non-Hodgkin's lymphoma (odds ratio 0.277, 95% CI: 0.124-0.622, P < 0.01), and treatment with ≥ four chemotherapy regimens (odds ratio 0.366, 95% CI: 0.167-0.799, P < 0.05) were associated significantly with failed mobilization. The rate of successful mobilizations was decreased in patients treated with purine analogues (odds ratio 0.323, 95% CI: 0.096-1.094, P = 0.07) but increased in female patients (odds ratio 1.961, CI: 0.943-4.080, P = 0.07). Patients who are characterized by the above negative features could benefit potentially from further improvement in the mobilization strategy.
authors.affiliation: Department of Hematology, Oncology and Internal Diseases, The Medical University of Warsaw, Poland. gbasak@ib.amwaw.edu.pl
authors.forename: Grzegorz W
authors.initials: GW
authors.lastname: Basak
authors.forename: Ozren
authors.initials: O
authors.lastname: Jaksic
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Koristek
authors.forename: Gabor
authors.initials: G
authors.lastname: Mikala
authors.forename: Jiri
authors.initials: J
authors.lastname: Mayer
authors.forename: Tamas
authors.initials: T
authors.lastname: Masszi
authors.forename: Boris
authors.initials: B
authors.lastname: Labar
authors.forename: Wieslaw
authors.initials: W
authors.lastname: Wiktor-Jedrzejczak
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001596:Benzylamines; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D002648:Child; D000080027:Cyclams; D005060:Europe; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation; D006571:Heterocyclic Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D000077269:Lenalidomide; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000628:therapy; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: D019380:Anti-HIV Agents; D000970:Antineoplastic Agents; D001596:Benzylamines; D001897:Boronic Acids; D000080027:Cyclams; D006571:Heterocyclic Compounds; D019653:Myeloablative Agonists; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide; D008558:Melphalan; C088327:plerixafor